These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
524 related articles for article (PubMed ID: 22632973)
21. Novel roles of Skp2 E3 ligase in cellular senescence, cancer progression, and metastasis. Wang G; Chan CH; Gao Y; Lin HK Chin J Cancer; 2012 Apr; 31(4):169-77. PubMed ID: 22200179 [TBL] [Abstract][Full Text] [Related]
22. Skp2 stabilizes Mcl-1 and confers radioresistance in colorectal cancer. Yu X; Zhou L; Liu W; Liu L; Gao F; Li W; Liu H Cell Death Dis; 2022 Mar; 13(3):249. PubMed ID: 35301297 [TBL] [Abstract][Full Text] [Related]
23. Recombinant human insulin-like growth factor binding protein 3 inhibits growth of human epidermal growth factor receptor-2-overexpressing breast tumors and potentiates herceptin activity in vivo. Jerome L; Alami N; Belanger S; Page V; Yu Q; Paterson J; Shiry L; Pegram M; Leyland-Jones B Cancer Res; 2006 Jul; 66(14):7245-52. PubMed ID: 16849573 [TBL] [Abstract][Full Text] [Related]
24. Cycle arrest and apoptosis in MDA-MB-231/Her2 cells induced by curcumin. Sun SH; Huang HC; Huang C; Lin JK Eur J Pharmacol; 2012 Sep; 690(1-3):22-30. PubMed ID: 22705896 [TBL] [Abstract][Full Text] [Related]
26. PKCα Attenuates Jagged-1-Mediated Notch Signaling in ErbB-2-Positive Breast Cancer to Reverse Trastuzumab Resistance. Pandya K; Wyatt D; Gallagher B; Shah D; Baker A; Bloodworth J; Zlobin A; Pannuti A; Green A; Ellis IO; Filipovic A; Sagert J; Rana A; Albain KS; Miele L; Denning MF; Osipo C Clin Cancer Res; 2016 Jan; 22(1):175-86. PubMed ID: 26350262 [TBL] [Abstract][Full Text] [Related]
27. The Skp2 Pathway: A Critical Target for Cancer Therapy. Cai Z; Moten A; Peng D; Hsu CC; Pan BS; Manne R; Li HY; Lin HK Semin Cancer Biol; 2020 Dec; 67(Pt 2):16-33. PubMed ID: 32014608 [TBL] [Abstract][Full Text] [Related]
28. Enhancement of the p27Kip1-mediated antiproliferative effect of trastuzumab (Herceptin) on HER2-overexpressing tumor cells. Marches R; Uhr JW Int J Cancer; 2004 Nov; 112(3):492-501. PubMed ID: 15382077 [TBL] [Abstract][Full Text] [Related]
29. Targeting the oncogenic E3 ligase Skp2 in prostate and breast cancer cells with a novel energy restriction-mimetic agent. Wei S; Chu PC; Chuang HC; Hung WC; Kulp SK; Chen CS PLoS One; 2012; 7(10):e47298. PubMed ID: 23071779 [TBL] [Abstract][Full Text] [Related]
30. Growth differentiation factor 15 (GDF15)-mediated HER2 phosphorylation reduces trastuzumab sensitivity of HER2-overexpressing breast cancer cells. Joshi JP; Brown NE; Griner SE; Nahta R Biochem Pharmacol; 2011 Nov; 82(9):1090-9. PubMed ID: 21803025 [TBL] [Abstract][Full Text] [Related]
31. SKP2 promotes the metastasis of pancreatic ductal adenocarcinoma by suppressing TRIM21-mediated PSPC1 degradation. Yuan J; Zhu Z; Zhang P; Ashrafizadeh M; Abd El-Aty AM; Hacımüftüoğlu A; Linnebacher CS; Linnebacher M; Sethi G; Gong P; Zhang X Cancer Lett; 2024 Apr; 587():216733. PubMed ID: 38360141 [TBL] [Abstract][Full Text] [Related]
32. Bcr-Abl-induced tyrosine phosphorylation of Emi1 to stabilize Skp2 protein via inhibition of ubiquitination in chronic myeloid leukemia cells. Chen JY; Wang MC; Hung WC J Cell Physiol; 2011 Feb; 226(2):407-13. PubMed ID: 20717963 [TBL] [Abstract][Full Text] [Related]
33. Cdh1-mediated Skp2 degradation by dioscin reprogrammes aerobic glycolysis and inhibits colorectal cancer cells growth. Zhou L; Yu X; Li M; Gong G; Liu W; Li T; Zuo H; Li W; Gao F; Liu H EBioMedicine; 2020 Jan; 51():102570. PubMed ID: 31806563 [TBL] [Abstract][Full Text] [Related]
34. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation. Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904 [TBL] [Abstract][Full Text] [Related]
35. t-Darpp Activates IGF-1R Signaling to Regulate Glucose Metabolism in Trastuzumab-Resistant Breast Cancer Cells. Lenz G; Hamilton A; Geng S; Hong T; Kalkum M; Momand J; Kane SE; Huss JM Clin Cancer Res; 2018 Mar; 24(5):1216-1226. PubMed ID: 29180608 [No Abstract] [Full Text] [Related]
36. MDM2-mediated degradation of SIRT6 phosphorylated by AKT1 promotes tumorigenesis and trastuzumab resistance in breast cancer. Thirumurthi U; Shen J; Xia W; LaBaff AM; Wei Y; Li CW; Chang WC; Chen CH; Lin HK; Yu D; Hung MC Sci Signal; 2014 Jul; 7(336):ra71. PubMed ID: 25074979 [TBL] [Abstract][Full Text] [Related]
37. A novel tumor suppressor ZBTB1 regulates tamoxifen resistance and aerobic glycolysis through suppressing Zhang P; Yang Y; Qian K; Li L; Zhang C; Fu X; Zhang X; Chen H; Liu Q; Cao S; Cui J J Biol Chem; 2020 Oct; 295(41):14140-14152. PubMed ID: 32690611 [TBL] [Abstract][Full Text] [Related]
38. Skp2 directs Myc-mediated suppression of p27Kip1 yet has modest effects on Myc-driven lymphomagenesis. Old JB; Kratzat S; Hoellein A; Graf S; Nilsson JA; Nilsson L; Nakayama KI; Peschel C; Cleveland JL; Keller UB Mol Cancer Res; 2010 Mar; 8(3):353-62. PubMed ID: 20197382 [TBL] [Abstract][Full Text] [Related]
39. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor. Tseng PH; Wang YC; Weng SC; Weng JR; Chen CS; Brueggemeier RW; Shapiro CL; Chen CY; Dunn SE; Pollak M; Chen CS Mol Pharmacol; 2006 Nov; 70(5):1534-41. PubMed ID: 16887935 [TBL] [Abstract][Full Text] [Related]
40. Skp2-dependent ubiquitination and activation of LKB1 is essential for cancer cell survival under energy stress. Lee SW; Li CF; Jin G; Cai Z; Han F; Chan CH; Yang WL; Li BK; Rezaeian AH; Li HY; Huang HY; Lin HK Mol Cell; 2015 Mar; 57(6):1022-1033. PubMed ID: 25728766 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]